Sanofi Inks $9.5B Blueprint Buyout to Expand Rare Disease Portfolio

Blueprint has a next-generation systemic mastocytosis treatment, called elenestinib, that Sanofi CEO Paul Hudson told analysts provides an “opportunity to grow through the ‘30s.”